Benzinga | Nov 2, 2021 10:50AM EDT

Esperion Therapeutics Q3 EPS $(2.62) Beats $(2.79) Estimate, Sales $10.90M Miss $12.85M Estimate

Esperion Therapeutics (NASDAQ:ESPR) reported quarterly losses of $(2.62) per share which beat the analyst consensus estimate of $(2.79) by 6.09 percent. This is a 14.66 percent increase over losses of $(3.07) per share from the same period last year. The company reported quarterly sales of $10.90 million which missed the analyst consensus estimate of $12.85 million by 15.18 percent. This is a 184.37 percent increase over sales of $3.83 million the same period last year.